Cita APA

de-la-Puente-Ovejero, L., Fernández-Rodríguez, A., Francoz, S., Aizpurua, G., Lomba-Riego, L., Drosten, M., . . . García-Alonso, S. (2026). RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

Citación estilo Chicago

de-la-Puente-Ovejero, Laura, et al. RAF1 As a Standalone Therapeutic Target in KRAS-driven Lung Adenocarcinoma: No Added Efficacy From Co-targeting ARAF, EGFR, or DDR1. 2026.

Cita MLA

de-la-Puente-Ovejero, Laura, et al. RAF1 As a Standalone Therapeutic Target in KRAS-driven Lung Adenocarcinoma: No Added Efficacy From Co-targeting ARAF, EGFR, or DDR1. 2026.